InspireMD Ltd.
This article was originally published in Start Up
Executive Summary
InspireMD has come up with a new generation of stents to reduce the risk of embolic showers, injury to the vessel wall, incomplete endothelium healing thrombosis, and other adverse events associated with coronary stenting procedures. The Israeli start-up's MGuard is a line of products consisting of expandable and flexible fishnet-style, micron-level nets that wrap around the stent and block emboli and plaque from detaching from the arterial wall.
You may also be interested in...
Embolic Protection: Unmet Clinical Need or Unneeded Technology
While the debate continues about whether embolic protection devices are really necessary, the space continues to generate interest from investors, start-ups and large companies looking for new technologies. Despite the unfulfilled promise of the past decade, interest has spread to new interventional applications such as percutaneous heart valves, indicating that this area remains a viable opportunity for start-ups.
Embolic Protection: Unmet Clinical Need or Unneeded Technology
While the debate continues about whether embolic protection devices are really necessary, the space continues to generate interest from investors, start-ups and large companies looking for new technologies. Despite the unfulfilled promise of the past decade, interest has spread to new interventional applications such as percutaneous heart valves, indicating that this area remains a viable opportunity for start-ups.
Start-Up Previews (10/20080
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Making Inroads in Predictive Toxicology," features profiles of Cellumen, GliaGen, Horizon Discovery and SimuGen. Plus these Start-Ups Across Health Care: Acacia Pharma, InspireMD, MicroTransponder and Quotient Diagnostics.